Cost regulators for the NHS in England and Wales have not approved funding for TiGenix and Takeda’s Alofisel – the first allogeneic stem cell therapy to be approved for use across the European Union – for use in Crohn’s patients in draft guidelines.
Read More
TiGenix and Takeda’s Alofisel has become the first allogeneic stem cell therapy to be approved for use across the European Union.
Read More
Seven therapies have been put forward for approval in the European Union, bringing closer new options for a range of conditions including Crohn’s disease, diabetes and cancer.
Read More
Takeda and TiGenix’ stem cell therapy has shown promise in inducing remission of perianal fistulas in patients with Crohn’s disease, according findings of a late-stage trial published in The Lancet.
Read More
